Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

'Cautious' clients hit revenues at S4 Capital

(Sharecast News) - Martin Sorrell's S4 Capital posted a sharp fall in quarterly revenues on Thursday, after nervous clients reined in spending amid the worsening macroeconomic backdrop. Like-for-like billings were up 8.6% at the advertising and marketing agency, at £463.3m. But revenues fell 14.3% on the same basis in the three months to March end to £178.1m.

All geographic regions saw a decline in revenues, including a 10.5% drop in the Americas, S4 Capital's biggest market by some distance.

S4 Capital did not provide a figure for operational earnings before interest, tax, depreciation and amortisation, other than to confirm it was line with expectations.

Executive chair Sorrell, who founded the business after more than three decades at WPP, said: "Trading in the first quarter reflects the continuing impact of, to say the least, volatile global macroeconomic conditions.

"As a result, clients remain cautious, with technology clients - which account for almost half our revenue - continuing to prioritise capital expenditure on AI over operating expenditure such as marketing."

As at 1130 BST, shares in the firm were down 3% at 25.0p.

Looking to the full year, Sorrell said the macroeconomic environment had become "even more challenging" in 2025.

"Assessing the impact of US imposed tariffs has been added to the three principal risks around US/China relations, Russia/Ukraine and Iran/Middle East. Clients, therefore, are likely to remain cautious," he said.

However, Sorrell said he still expected an improved performance in the second half, as clients assessed the impact of tariffs and revenue from new business flows through.

He continued: "We will continue to focus on our cost base and will take further action to support profitability, and expect net revenue and operational EBITDA to be broadly similar to 2024, on a constant currency basis, with a further reduction in net debt."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.